RISPERIDON- IMPLANTATFORMULIERUNG

European patent · EP2854858 · In force

Register entry

Publication number
EP2854858
Application number
EP13726003
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
May 31, 2013
Published
Apr 8, 2015
Granted
Dec 10, 2025
Protection ends at the latest
May 30, 2033
Next annual fee due
May 31, 2026
IPC classes
A61K 47/34 (2017.01)
Priority
EP 12170362 31.05.2012
PCT application
PCT/EP2013/061320 31.05.2013
PCT publication
WO2013/178812 05.12.2013
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Oct 21, 2026

    Change

    Published in Swissreg on 21.10.2026

  2. Dec 10, 2025

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 10.12.2025

Parties

Holder

LABORATORIOS FARMACEUTICOS ROVI, S.A.

Laboratorios Farmacéuticos Rovi, S.A.

C/ Julián Camarillo 35, 28037 Madrid, ES

Inventor

GUTIERRO ADURIZ, Ibon

E-28037 Madrid, ES

FRANCO RODRÍGUEZ, Guillermo

E-28037 Madrid, ES

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.